Can Moderna Achieve Its Most Ambitious Goal Yet?
(NASDAQ: MRNA) and ambition seem to go hand and hand. The company doesn't fear taking on challenges, as it demonstrated during the earliest days of the pandemic when it brought its coronavirus vaccine from the drawing board to market in less than a year. Investors rewarded the biotech company for its audacity and scientific strengths, driving up the share price by 1,700% in just 1 1/2 years..
Recent times have been more difficult for Moderna shares, though. As we head toward a post-pandemic world and demand for coronavirus vaccines declines, investors have worried about Moderna's dependence on its one and only product. As a result, the stock has retreated, slipping about 40% this year.
But Moderna's most exciting days actually may be ahead rather than in the past -- at least, if the company reaches its most ambitious goal yet. Can it happen?
Source Fool.com
Moderna Inc. Stock
The stock is one of the favorites of our community with 25 Buy predictions and 4 Sell predictions.
With a target price of 124 € there is potential for a 126.11% increase which would mean more than doubling the current price of 54.84 € for Moderna Inc..
